Cutaneous Radiation Injury
Radiation exposure is a real threat in today’s world and to national security. Injury to the skin and underlying tissues from subjection to ionizing radiation, commonly referred to as Cutaneous Radiation Injury (CRI), is currently an unsolved issue. No current standards of care exist for CRI treatment. CRI patients experience moist desquamation, ulceration, and/or necrosis. Severe cases of CRI can become fatal.
Pre-clinical studies show that compared to controls, keratin cream improved metrics of ulceration, epidermal atrophy, dermal inflammation. Treatment with keratin cream accelerated healing and reduced the appearance of moist desquamation in CRI.
Radiation Dermatitis (RD) can profoundly impact a patient’s quality of life, with effects ranging from mild to severe. Approximately 85% of cancer patients who undergo radiation therapy treatment experience at least some degree of RD. Roughly 25% of patients experience serious symptoms including moist desquamation, ulceration, and necrosis. RD can interrupt radiation therapy, resulting in inadequate or delayed treatment.
With no existing effective standard of care treatment, there is a significant unmet need for products that decrease severity and injury time. Clinical studies show that KeraStat Cream reduces the severity of RD compared to the current standard of care.